Cell Genesys, Inc. (CEGE)

CAPS Rating:

A biotechnology company focused on the development and commercialization of novel biological therapies for patients with cancer.

View All Commentary (CEGE)

Recs

11

Avatar upanddown100 (< 20) Submitted: 2/16/07 12:21 PM : Start Price: $3.49 CEGE Score: -45.93

The stock price is disproportionally weighed down by it's debt. With money so cheap, CEGE has plenty of cash that it would prefer to put to work rather than to pay down debt. And it is putting it to work on cures for major killers- prostate cancer and pancreatic cancer. Look for this puppy to be acquired at $10/share or for a big pharma to take a big interest before the end of June.

Report this Post Replies: 2 | Reply

Avatar riley20 (< 20) Submitted: 2/26/07 5:32 PM

Recs: 0 | Rec This

actually cege has no debt unless u want to count convertables. It's fully diluted shares are 65mil. It has lots of cash but that will be gone in 2 yrs funding two pivital phIII trials. the real buzz is it's phI trial with medx that just reported amazing results though it was a small sample. this is a cheap stock with great prospects but not without it's risks.

Report this Post Reply

Avatar lquadland10 (< 20) Submitted: 4/18/07 5:14 PM

Recs: 0 | Rec This

i agree.

Report this Post Reply

Cell Genesys, Inc. (CEGE)

11

Featured Broker Partners